The development and validation of a patient-reported outcome measure to assess financial hardship among older cancer survivors in China: hardship and recovery with distress survey.
financial hardship
financial toxicity
health outcome
older cancer survivors
patient-reported outcome measure
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
26
01
2023
accepted:
28
03
2023
medline:
8
5
2023
pubmed:
8
5
2023
entrez:
8
5
2023
Statut:
epublish
Résumé
Financial hardship has been described as a patient's economic experiencefollowing cancer-related treatment. Standardized patient-reported outcome measures(PROM) to assess this distress has not been well-studied, especially among older cancer survivors. The aim of this study was to develop and validate PROM for assessing the financial hardship of older cancer survivors in China. Items were generated using qualitative interviews and literature review. Items were screened based on Delphi expert consultation and patients' opinions. Item response theory (IRT) and classical test theory (CTT) were used to help reduce items. Retained items formed a pilot instrument that was subjected to psychometric testing. A cut-off score for the new instrument for predicting poor quality of life was identified by receiver operating characteristic (ROC) analysis. Qualitative interviews and literature review generated 135 items, which were reduced to 60 items because of redundancy. Following Delphi expert consultation and patients' evaluation, 24 items with high importance were extracted. Sixteen items were selected due to satisfactory statistical analysis based on CTT and IRT. Ten items were retained and comprised 2 domains after loadings in exploratory factor analysis (EFA). Internal consistency was satisfactory (α = 0.838). Test-retest reliability was good (intraclass correlation, 0.909). The ROC analysis suggested that the cut-off of 18.5 yielded an acceptable sensitivity and specificity. The PROM for Hardship and Recovery with Distress Survey (HARDS) consists of 10 items that specifically reflect the experiences of financial hardship among older Chinese cancer survivors, and it also showed good reliability and validity in clinical settings.
Sections du résumé
Background
UNASSIGNED
Financial hardship has been described as a patient's economic experiencefollowing cancer-related treatment. Standardized patient-reported outcome measures(PROM) to assess this distress has not been well-studied, especially among older cancer survivors.
Objective
UNASSIGNED
The aim of this study was to develop and validate PROM for assessing the financial hardship of older cancer survivors in China.
Methods
UNASSIGNED
Items were generated using qualitative interviews and literature review. Items were screened based on Delphi expert consultation and patients' opinions. Item response theory (IRT) and classical test theory (CTT) were used to help reduce items. Retained items formed a pilot instrument that was subjected to psychometric testing. A cut-off score for the new instrument for predicting poor quality of life was identified by receiver operating characteristic (ROC) analysis.
Results
UNASSIGNED
Qualitative interviews and literature review generated 135 items, which were reduced to 60 items because of redundancy. Following Delphi expert consultation and patients' evaluation, 24 items with high importance were extracted. Sixteen items were selected due to satisfactory statistical analysis based on CTT and IRT. Ten items were retained and comprised 2 domains after loadings in exploratory factor analysis (EFA). Internal consistency was satisfactory (α = 0.838). Test-retest reliability was good (intraclass correlation, 0.909). The ROC analysis suggested that the cut-off of 18.5 yielded an acceptable sensitivity and specificity.
Conclusions
UNASSIGNED
The PROM for Hardship and Recovery with Distress Survey (HARDS) consists of 10 items that specifically reflect the experiences of financial hardship among older Chinese cancer survivors, and it also showed good reliability and validity in clinical settings.
Identifiants
pubmed: 37152015
doi: 10.3389/fonc.2023.1151465
pmc: PMC10162643
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1151465Informations de copyright
Copyright © 2023 Liu, Zhang, Su, Sun, Shao, Cheng and Yao.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Health Soc Care Community. 2022 Nov;30(6):e3829-e3842
pubmed: 36259247
Asia Pac J Oncol Nurs. 2022 Apr 27;9(8):100071
pubmed: 35692729
Ann Oncol. 2019 Jul 1;30(7):1061-1070
pubmed: 31046080
Lancet Reg Health West Pac. 2021 Nov 09;18:100301
pubmed: 35024647
EClinicalMedicine. 2020 Jan 31;20:100269
pubmed: 32300733
J Pain Symptom Manage. 2019 Mar;57(3):646-660.e1
pubmed: 30550833
Clin Gastroenterol Hepatol. 2021 Jul;19(7):1377-1386.e5
pubmed: 32526341
PLoS One. 2018 Mar 7;13(3):e0193273
pubmed: 29513712
Cancer Med. 2019 Dec;8(18):7859-7868
pubmed: 31650699
BMJ Open. 2018 Jul 11;8(7):e019919
pubmed: 29997135
J Oncol Pract. 2014 Sep;10(5):e368-72
pubmed: 24865219
JAMA Netw Open. 2020 Dec 1;3(12):e2025810
pubmed: 33284337
Front Oncol. 2022 Feb 02;11:819313
pubmed: 35186720
J Natl Compr Canc Netw. 2019 Oct 1;17(10):1184-1192
pubmed: 31590147
J Natl Cancer Inst. 2016 Oct 20;109(2):
pubmed: 27754926
J Cancer Educ. 2019 Apr;34(2):242-251
pubmed: 29170930
Psychooncology. 2022 Apr;31(4):661-670
pubmed: 34784087
Qual Health Res. 2020 Sep;30(11):1749-1761
pubmed: 32564651
Asia Pac J Oncol Nurs. 2022 Jul 05;9(11):100113
pubmed: 36158706
Oncology (Williston Park). 2013 Feb;27(2):80-1, 149
pubmed: 23530397
BMJ Open. 2019 Sep 9;9(9):e031485
pubmed: 31501130
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
PLoS One. 2017 Nov 10;12(11):e0187100
pubmed: 29125837
Cancer. 2017 Feb 1;123(3):476-484
pubmed: 27716900
Cancer. 2022 Jul 1;128(13):2455-2462
pubmed: 35417565
Int J Clin Pharm. 2019 Oct;41(5):1174-1183
pubmed: 31254152
Support Care Cancer. 2020 Sep;28(9):4477-4485
pubmed: 31925533
Cancer. 2020 Jul 15;126(14):3312-3321
pubmed: 32396242
BMJ Open. 2021 Oct 19;11(10):e047699
pubmed: 34667000
Cancer. 2020 Sep 1;126(17):4042-4050
pubmed: 32603521
Qual Life Res. 2021 Aug;30(8):2197-2218
pubmed: 33818733
Cancer. 2014 Oct 15;120(20):3245-53
pubmed: 24954526
Cancer Commun (Lond). 2020 May;40(5):205-210
pubmed: 32359212
Cancer Biol Med. 2022 Aug 30;19(8):
pubmed: 36069534
Support Care Cancer. 2021 Jun;29(6):3219-3233
pubmed: 33094357
Support Care Cancer. 2022 Nov;30(11):9433-9440
pubmed: 35917024
BMC Public Health. 2022 Sep 20;22(1):1783
pubmed: 36127650
Qual Life Res. 2018 May;27(5):1147-1157
pubmed: 29435801
BMJ. 2019 Jun 19;365:l2349
pubmed: 31217222